View Future GrowthLIR Life Sciences 過去の業績過去 基準チェック /06LIR Life Sciencesの収益は年平均-903.2%で減少しているが、Pharmaceuticals業界はgrowingで9.4%年平均の収益となった。主要情報-903.23%収益成長率92.22%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率n/a株主資本利益率-245.66%ネット・マージンn/a前回の決算情報31 Jan 2026最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Jan 23LIR Life Sciences Corp. Completes Design of Ex Vivo Animal Study to Evaluate Novel Transdermal Agents for Transport of Larger Therapeutic MoleculesLIR Life Sciences Corp. announced the completion of a study design for an ex vivo porcine skin investigation that is designed to evaluate whether novel transdermal agents can enhance the transdermal penetration of therapeutic macromolecules across a wide molecular size range, spanning approximately 5kDa up to antibody scale (~150kDa). In particular, the study will test whether transdermal agents can help much larger medicines move through skin effectively, which could potentially open the door to developing certain therapies without injections. Working with its scientific partners, LIR has finalized a controlled experimental framework using full thickness porcine skin, which is commonly accepted as one of the most relevant models for human skin permeability. The study is designed to compare transdermal agent-containing formulations with matched controls that contain the same macromolecular payloads without transdermal agents. Penetration depth and distribution will be evaluated using confocal microscopy together with quantitative fluorescence-based measurements collected at predefined time points. These analyses are intended to help determine whether the transdermal agents can meaningfully facilitate the movement of macromolecular therapeutics through the skin to a measurable degree. Completion of the design phase allows LIR to proceed towards formal study execution, which is expected to occur in First Quarter, 2026. The results are expected to inform which categories of larger therapeutic molecules may ultimately be compatible with skin applied, needle free delivery strategies.お知らせ • Jan 16LIR Life Sciences Corp. Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation Glp/Gip-Based Obesity TherapiesLIR Life Sciences Corp. announced the launch of a controlled comparative animal study designed to evaluate cell-penetrating peptide (CPP) mediated, needle-free transdermal delivery of second generation GLP/GIP-based obesity therapies. This in vivo study represents an important next step towards advancing LIR's transdermal platform from design-stage planning into functional testing in a small animal model. Working with its scientific collaborators, LIR will assess whether a CPP-enabled, skin-applied formulation of a representative second generation GLP/G IP-based obesity therapy can achieve meaningful biological activity when delivered through the skin. Study animals will receive either a topical CPP formulation or a standard subcutaneous injection, followed by a controlled glucose challenge. Blood glucose levels will be measured over time to compare how effectively each route of administration supports glucose control. The study will use a standard glucose tolerance test, a well-established method in metabolic research and clinical practice. Incretin-based therapies that are working as intended have been shown to help keep the blood sugar curve lower and flatter after the glucose load. If the CPP-enabled transdermal formulation is found to deliver sufficient drug into circulation, LIR expects that animals treated via the skin should show more stable glucose profiles. By focusing on GLP/GIP- based incretin therapies as a class, rather than a single branded product, the study is intended to probe the broader applicability of the CPP-enabled trans Dermal platform. The resulting data are expected to help define where needle-free delivery may match or approach injectable performance and to guide selection of the most promising molecules for further development and potential IND-enabling work. These efforts align with LIR's objective to create patient-friendly, scalable alternatives to injectable incretin therapies for obesity and related metabolic conditions. Needle-free, skin-applied treatments could simplify administration, improve adherence, and reduce treatment burden for patients who might otherwise require frequent injections for long-term weight and glucose management. LIR Life Sciences aims to address the global burden of obesity with practical solutions based on established compounds and proven science.収支内訳LIR Life Sciences の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:BBCM.F 収益、費用、利益 ( )CAD Millions日付収益収益G+A経費研究開発費31 Jan 260-32031 Oct 250-11031 Jul 25000030 Apr 250000質の高い収益: BBCM.Fは現在利益が出ていません。利益率の向上: BBCM.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: BBCM.Fの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: BBCM.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: BBCM.Fは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -4.8% ) と比較することは困難です。株主資本利益率高いROE: BBCM.Fは現在利益が出ていないため、自己資本利益率 ( -245.66% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/05 08:22終値2026/06/05 00:00収益2026/01/31年間収益2025/04/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋LIR Life Sciences Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jan 23LIR Life Sciences Corp. Completes Design of Ex Vivo Animal Study to Evaluate Novel Transdermal Agents for Transport of Larger Therapeutic MoleculesLIR Life Sciences Corp. announced the completion of a study design for an ex vivo porcine skin investigation that is designed to evaluate whether novel transdermal agents can enhance the transdermal penetration of therapeutic macromolecules across a wide molecular size range, spanning approximately 5kDa up to antibody scale (~150kDa). In particular, the study will test whether transdermal agents can help much larger medicines move through skin effectively, which could potentially open the door to developing certain therapies without injections. Working with its scientific partners, LIR has finalized a controlled experimental framework using full thickness porcine skin, which is commonly accepted as one of the most relevant models for human skin permeability. The study is designed to compare transdermal agent-containing formulations with matched controls that contain the same macromolecular payloads without transdermal agents. Penetration depth and distribution will be evaluated using confocal microscopy together with quantitative fluorescence-based measurements collected at predefined time points. These analyses are intended to help determine whether the transdermal agents can meaningfully facilitate the movement of macromolecular therapeutics through the skin to a measurable degree. Completion of the design phase allows LIR to proceed towards formal study execution, which is expected to occur in First Quarter, 2026. The results are expected to inform which categories of larger therapeutic molecules may ultimately be compatible with skin applied, needle free delivery strategies.
お知らせ • Jan 16LIR Life Sciences Corp. Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation Glp/Gip-Based Obesity TherapiesLIR Life Sciences Corp. announced the launch of a controlled comparative animal study designed to evaluate cell-penetrating peptide (CPP) mediated, needle-free transdermal delivery of second generation GLP/GIP-based obesity therapies. This in vivo study represents an important next step towards advancing LIR's transdermal platform from design-stage planning into functional testing in a small animal model. Working with its scientific collaborators, LIR will assess whether a CPP-enabled, skin-applied formulation of a representative second generation GLP/G IP-based obesity therapy can achieve meaningful biological activity when delivered through the skin. Study animals will receive either a topical CPP formulation or a standard subcutaneous injection, followed by a controlled glucose challenge. Blood glucose levels will be measured over time to compare how effectively each route of administration supports glucose control. The study will use a standard glucose tolerance test, a well-established method in metabolic research and clinical practice. Incretin-based therapies that are working as intended have been shown to help keep the blood sugar curve lower and flatter after the glucose load. If the CPP-enabled transdermal formulation is found to deliver sufficient drug into circulation, LIR expects that animals treated via the skin should show more stable glucose profiles. By focusing on GLP/GIP- based incretin therapies as a class, rather than a single branded product, the study is intended to probe the broader applicability of the CPP-enabled trans Dermal platform. The resulting data are expected to help define where needle-free delivery may match or approach injectable performance and to guide selection of the most promising molecules for further development and potential IND-enabling work. These efforts align with LIR's objective to create patient-friendly, scalable alternatives to injectable incretin therapies for obesity and related metabolic conditions. Needle-free, skin-applied treatments could simplify administration, improve adherence, and reduce treatment burden for patients who might otherwise require frequent injections for long-term weight and glucose management. LIR Life Sciences aims to address the global burden of obesity with practical solutions based on established compounds and proven science.